Network Version
Oxethazaine Data Sheet
| Product Name: | Oxethazaine |
 |
|---|---|---|
| CAS No.: | 126-27-2 | |
| Cat. No.: | HY-B0955 | |
| MWt: | 467.64 | |
| Formula: | C28H41N3O3 | |
| Purity : | >98% | |
| Solubility: | DMSO : ≥ 50 mg/mL (106.92 mM) | |
| Mechanisms: | Target: Neurological Disease | |
| Biological Activity: | ||
| Oxethazaine (Oxetacaine), a precursor of phentermine acidic, is an acid-resistent and orally active analgesic agent. Oxethazaine (Oxetacaine) has the potential for the relief of pain associated with peptic ulcer disease or esophagitis[1]. In Vivo: Oxetacaine (intraperitoneal injection; 5, 10, and 15 mg/kg; during days 4–11) doses induces significant conditioned place preference (CPP), and there are no differences among the groups. While its postive control group phentermine only 3 mg/kg causes significant CPP[1].. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com